Abstract
Introduction
Adalimumab (ADM) is a recombinant human monoclonal antibody (anti-TNFα) used to treat inflammatory bowel diseases. It can cause kidney injury (KI).
Case diagnosis/treatment
We describe two pediatric patients with Crohn’s disease (CD) in whom ADM therapy was associated with kidney injury (KI). The drug was discontinued in both cases. For the first patient, changes were irreversible despite intensive glucocorticosteroid (GCS) therapy. For the second patient, discontinuation of ADM led to an improvement in kidney function.
Conclusions
Due to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.
Similar content being viewed by others
References
Sandys V, Moloney B, Lane L, Qazi J, Doyle B, Barry M, Leavey S, Conlon P (2018) Granulomatous interstitial nephritis secondary to adalimumab therapy. Clin Kidney J 11:219–221. https://doi.org/10.1093/ckj/sfx104
Graziano F, Busè M, Cassata N, Lentini VL, Citrano M (2022) IgA nephropathy in a child: Crohn’s disease-associated or adalimumab induced? Curr Med Res Opin 38:139–143. https://doi.org/10.1080/03007995.2021.2015155
Chen TJ, Yang YF, Huang PH, Lin HH, Huang CC (2010) Permanent renal loss following tumor necrosis factor α antagonists for arthritis. Rheumatol Int 30:1077–1079. https://doi.org/10.1007/s00296-009-1016-2
Usui J, Salvatore SP, Yamagata K, Seshan SV (2023) Clinicopathologic spectrum of renal lesions following anti-TNF-α inhibitor therapy: a single center experience. Kidney360 4:363–373. https://doi.org/10.34067/KID.0000000000000063
Tamura H (2023) IgA nephropathy associated with Crohn’s disease. World J Methodol 13:67–78. https://doi.org/10.5662/wjm.v13.i3.67
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Skoczyński, K., Koziej, J., Szymańska, S. et al. Adalimumab as a cause of kidney injury in patients with Crohn’s disease. Pediatr Nephrol (2024). https://doi.org/10.1007/s00467-024-06338-0
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00467-024-06338-0